Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 30 | 27 | −3 |
| Shares | 1.19M | 3.55M | +2.35M (+197.2%) |
| Value | $1.30M | $3.70M | +$2.40M (+184.7%) |
New holders (2)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Highbridge Capital Management LLC | 2,413,487 | $2.51M | 0.04% |
| Susquehanna International Group, LLP | 222,261 | $231.0K | 0.00% |
Sold out (5)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Spire Wealth Management | 148,800 | $162.0K |
| Virtu Financial LLC | 28,816 | $31.0K |
| Millennium Management LLC | 19,223 | $21.0K |
| Captrust Financial Advisors | 800 | $1.00K |
| JPMorgan Chase & Co | 395 | $0 |